Body Composition Analysis for Patient With Lung Cancer Using Computed Tomography Image Analysis

Lung Cancer Clinical Trial

— BAT-SCAN  

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01887769
• Other study ID #: 20824
• Status: Recruiting
• Phase: N/A
• First received: February 13, 2013
• Last updated: January 5, 2017
• Start date: May 2012
• Est. completion date: October 2017

Study information

• Verified date: January 2017
• Source: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Ethics Review Committee
• Study type: Observational

Clinical Trial Summary

Rationale: With 1.6 million new cases diagnosed each year and 1.3 million deaths, lung cancer is the leading cancer-related death worldwide and it represents a pressing health issue. Patients with lung cancer are more likely to experience cachexia, a severe debilitating disorder causing fatigue, weight loss, muscle wasting and associated with reduced physical function, increased chemotherapy toxicity and reduced survival. This syndrome occurring in about 80% of advanced cancer patients is the direct cause of death in about 20% of cases. However, despite the importance of cachexia in lung cancer, it has been mainly studied from several assessment methods which do not usually differentiate muscle from other tissues.

Aim: To analyze body composition of patients with lung cancer at diagnosis using computed tomography (CT-Scan) image analysis.

Methods: This is a retrospective study extending over a period of 3 years conducted at the Institut universitaire de cardiologie et de pneumologie de Québec (2009-2012). We listed patients newly diagnosed with lung cancer who had a thoraco-abdominal CT-scan performed in our institution. Following the collection of clinical data from patient records, we used SliceOmatic software to quantify muscle area, visceral fat area and subcutaneous fat area from a single abdominal cross-sectional image at the level of the third lumbar vertebra.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: October 2017
• Est. primary completion date: July 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Men or women

• Between 40-80 years of age

• Primary lung cancer diagnosed between 2009 and 2012

• CT-Scan done at the time of the diagnosis

Exclusion Criteria:

• Chemotherapy, radiotherapy or surgery at the time of the first Ct-Scan image

• History of other cancer (during the last five years)

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Locations

Country	Name	City	State
Canada	Institut universitaire de cardiologie et de pneumologie de Québec	Québec	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of muscle area (cm2/m2) at the level of the third lumbar vertebra		at the time of the diagnosis of lung cancer and one year following it.	No
Primary	Change of fat area (cm2/m2) at the level of the third lumbar vertebra		at the time of the diagnosis of lung cancer and one year following it.	No
Secondary	days of survival		From the time of the diagnosis of lung cancer until one year	No